Previous Article | Next Article ![]()
Infect Immun, June 1998, p. 2951-2959, Vol. 66, No. 6
Mycobacteria Research Laboratories,
Received 20 October 1997/Returned for modification 8 January
1998/Accepted 12 March 1998
The results of this study provide the first evidence that two
completely separate vaccine approaches, one based on a subunit vaccine
consisting of a mild adjuvant admixed with purified culture filtrate
proteins and enhanced by the cytokine interleukin-2 and the second
based on immunization with DNA encoding the Ag85A protein secreted by
Mycobacterium tuberculosis, could both prevent the onset of
caseating disease, which is the hallmark of the guinea pig aerogenic
infection model. In both cases, however, the survival of vaccinated
guinea pigs was shorter than that conferred by Mycobacterium bovis BCG, with observed mortality of these animals probably due to consolidation of lung tissues by lymphocytic granulomas. An additional characteristic of these approaches was that neither induced
skin test reactivity to commercial tuberculin. These data thus provide
optimism that development of nonliving vaccines which can generate
long-lived immunity approaching that conferred by the BCG vaccine is a
feasible goal.
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Evaluation of New Vaccines in the Mouse and Guinea
Pig Model of Tuberculosis
*
Corresponding author. Mailing address: Mycobacteria
Research Laboratories, Department of Microbiology, Colorado State
University, Fort Collins, CO 80523. Phone: (970) 491-5777. Fax: (970)
491-5125. E-mail: iorme{at}lamar.colostate.edu.
Infect Immun, June 1998, p. 2951-2959, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|